Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis

European Journal of Neurology

Volumn 18, Issue 11, 2011, Pages 1350-1357

  Chien, P J ^a   Yeh, J H ^b   Chiu, H C ^b   Hsueh, Y M ^a   Chen, C T ^a   Chen, M C ^a   Shih, C M ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acetylcholine receptor antibody; Myasthenia gravis; NK cell cytotoxicity; Plasmapheresis

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; PREDNISONE; PYRIDOSTIGMINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD FILTRATION; CELL ISOLATION; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MYASTHENIA GRAVIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMAPHERESIS; PRIORITY JOURNAL; TARGET CELL;

ADULT; AGED; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMAPHERESIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053908160     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03424.x     Document Type: Article

References (48)

1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006; 116: 2843-2854.
2. Vincent A, Newsom Davis J. Anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1980; 43: 590-600.
3. Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010; 43: 428-435.
4. Díaz-Manera J, Rojas-García R, Illa I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacothe 2009; 10: 1329-1342.
5. Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000; 247: 510-513.
6. Yücesan C, Arslan O, Arat M, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci 2007; 36: 103-107.
7. Yeh JH, Chiu HC. Double filtration plasmapheresis in myasthenia gravis-analysis of clinical efficacy and prognostic parameters. Acta Neurol Scand 1999; 100: 305-309.
8. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
9. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5: 1260-1265.
10. Morandi B, Bougras G, Muller WA, Ferlazzo G, Münz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol 2006; 36: 2394-2400.
11. Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpfennig KW, Cantor H. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007; 26: 593-604.
12. Lanier LL. The origin and functions of natural killer cells. Clin Immunol 2000; 95: S14-S18.
13. Perricone R, Perricone C, De Carolis C, Shoenfeld Y. NK cells in autoimmunity: a two-edged weapon of the immune system. Autoimmun Rev 2008; 7: 384-390.
14. Shi FD, Wang HB, Li H, et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000; 1: 245-251.
15. Rauch HC, Montgomery IN, Kaplan J. Natural killer cell activity in multiple sclerosis and myasthenia gravis. Immunol Invest 1985; 14: 427-434.
16. Kott E, Hahn T, Huberman M, Levin S, Schattner A. Interferon system and natural killer cell activity in myasthenia gravis. Q J Med 1990; 76: 951-960.
17. Moretta A, Bottino C, Pende D, et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990; 172: 1589-1598.
18. Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol 2009; 16: 1318-1322.
19. Chang L, Gusewitch GA, Chritton DB, Folz JC, Lebeck LK, Nehlsen-Cannarella SL. Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods 1993; 166: 45-54.
20. Piriou L, Chilmonczyk S, Genetet N, Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity inhuman and in different animal species. Cytometry 2000; 41: 289-297.
21. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983; 33: 1316-1321.
22. Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity 2002; 35: 1-14.
23. Schepis D, Gunnarsson I, Eloranta ML, et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 2009; 126: 140-146.
24. Izumi Y, Ida H, Huang M, et al. Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell. J Lab Clin Med 2006; 147: 242-249.
25. Szodoray P, Papp G, Horvath IF, et al. Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol 2009; 157: 343-349.
26. Horikawa M, Hasegawa M, Komura K, et al. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Invest Dermatol 2005; 125: 731-737.
27. Chuang YH, Lian ZX, Tsuneyama K, et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 2006; 26: 232-240.
28. Takahashi H, Amagai M, Tanikawa A, et al. T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J Invest Dermatol 2007; 127: 324-330.
29. Hidaka Y, Amino N, Iwatani Y, et al. Increase in peripheral natural killer cell activity in patients with autoimmune thyroid disease. Autoimmunity 1992; 11: 239-246.
30. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 15: 3146-3151.
31. Lünemann A, Lünemann JD, Münz C. Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 2009; 15: 352-358.
32. Suzuki Y, Onodera H, Tago H, et al. Altered populations of natural killer cell and natural killer T cell subclasses in myasthenia gravis. J Neuro immunol 2005; 167: 186-189.
33. Nguyen S, Morel V, Le Garff-Tavernier M, et al. Persistence of CD16+/CD56-/2B4+ natural killer cells: a highly dysfunctional NK subset expanded in ocular myasthenia gravis. J Neuro immunol 2006; 179: 117-125.
34. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology 2009; 126: 458-465.
35. Yeh JH, Chien PJ, Hsueh YM, Shih CM, Chiu HC. Changes in the lymphocyte subset after double-filtration plasmapheresis. Am J Clin Pathol 2007; 128: 940-944.
36. Yoshii F, Shinohara Y. Natural killer cells in patients with Guillain-Barré syndrome. J Neurol Sci 1998; 7: 175-178.
37. Park YW, Kee SJ, Cho YN, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1753-1763.
38. Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30-R37.
39. Richter J, Benson V, Grobarova V, et al. CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. Clin Immunol 2010; 136: 139-147.
40. Infante-Duarte C, Weber A, Krätzschmar J, et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 2005; 19: 1902-1904.
41. Lorini R, Moretta A, Valtorta A, et al. Cytotoxic activity in children with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994; 23: 37-42.
42. Gao N, Jennings P, Yuan D. Requirements for the natural killer cell-mediated induction of IgG1 and IgG2a expression in B lymphocytes. Int Immunol 2008; 20: 645-657.
43. Jennings P, Yuan D. NK cell enhancement of antigen presentation by B lymphocytes. J Immunol 2009; 182: 2879-2887.
44. Lefvert AK, Bergström K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978; 41: 394-403.
45. Takeo G, Motomura M, Mats H, et al. Effect of myasthenic IgG on degradation of junctional acetylcholine receptor. Muscle Nerve 1993; 16: 840-848.
46. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 1978; 28: 266-272.
47. Scott MJ, Hoth JJ, Turina M, Woods DR, Cheadle WG. Interleukin-10 suppresses natural killer cell but not natural killer T cell activation during bacterial infection. Cytokine 2006; 21: 79-86.
48. Shi FD, Zhou Q. Natural killer cells as indispensable players and therapeutic targets in autoimmunity. Autoimmunity 2011; 44: 3-10.